🇺🇸 Ceftolozane-tazobactam in United States

86 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 17 reports (19.77%)
  2. Off Label Use — 10 reports (11.63%)
  3. Multiple Organ Dysfunction Syndrome — 9 reports (10.47%)
  4. Clostridium Difficile Infection — 8 reports (9.3%)
  5. Sepsis — 8 reports (9.3%)
  6. Candida Infection — 7 reports (8.14%)
  7. Condition Aggravated — 7 reports (8.14%)
  8. Neutropenia — 7 reports (8.14%)
  9. Septic Shock — 7 reports (8.14%)
  10. Product Use In Unapproved Indication — 6 reports (6.98%)

Source database →

Other Infectious Disease approved in United States

Frequently asked questions

Is Ceftolozane-tazobactam approved in United States?

Ceftolozane-tazobactam does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Ceftolozane-tazobactam in United States?

National University of Singapore is the originator. The local marketing authorisation holder may differ — check the official source linked above.